表紙
市場調查報告書
商品編碼
997013

偏頭痛治療的全球市場(2021年∼2025年)

Global Migraine Therapeutics Market 2021-2025

出版日期: | 出版商: TechNavio (Infiniti Research Ltd.) | 英文 120 Pages | 訂單完成後即時交付

價格
  • 全貌
  • 簡介
  • 目錄
簡介

偏頭痛治療的市場規模在2021年∼2025年的預測期間內,預計將以5%的年複合成長率增長,並成長到10億6,000萬美元。

偏頭痛治療市場相關之本報告提供整體分析,市場規模與預測,趨勢,涵括成長要素,課題,以及約25位供應商的供應商分析。

市場成長的主要因素有為偏頭痛困苦的患者數增加和偏頭痛預防藥的批准數量增加。尤其偏頭痛患者人數的增加也有望促進市場增長。

這份報告提供偏頭痛治療的世界市場調查,提供市場概要,市場成長要素及阻礙因素分析,市場機會,產品·治療·各地區的市場規模的變化與預測,競爭情形,主要企業的簡介等系統性資訊。

目錄

摘要整理

市場形勢

市場規模

  • 市場定義
  • 市場區隔分析
  • 市場規模(2020年)
  • 市場規模預測(2020年∼2025年)

波特的五力分析

各產品

  • 市場區隔
  • 各產品比較
  • 醫藥品
  • 設備
  • 各產品的市場機會

不同治療

  • 預防的治療
  • 挫折療法

客戶形勢

各地區

  • 各地區市場區隔
  • 各地區比較
  • 北美
  • 歐洲
  • 亞洲
  • 其他地區
  • 主要國家
  • 地區的市場機會
  • 市場推動因素
  • 市場課題
  • 市場趨勢

業者情勢

  • 業者情勢
  • 創造性破壞狀況
  • 競爭模式

供應商分析

  • 交易廠商
  • 供應商的市場定位
  • AbbVie Inc.
  • Amgen Inc.
  • Eli Lilly and Co.
  • eNeura Inc.
  • GlaxoSmithKline Plc
  • Grunenthal GmbH
  • H. Lundbeck AS
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Upsher-Smith Laboratories LLC

附錄

目錄
Product Code: IRTNTR70189

Technavio has been monitoring the migraine therapeutics market and it is poised to grow by $ 1.06 bn during 2021-2025 progressing at a CAGR of 5% during the forecast period. Our report on migraine therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the increase in the number of patients suffering from migraine and rise in the number of approvals for preventive drugs for migraine. In addition, increase in the number of patients suffering from migraine is anticipated to boost the growth of the market as well.

The migraine therapeutics market analysis includes product segment and geographical landscapes.

Technavio's migraine therapeutics market is segmented as below:

By Product

  • drugs
  • devices

By Geographical Landscapes

  • North America
  • Europe
  • Asia
  • ROW

This study identifies the rising advances in migraine therapeutics as one of the prime reasons driving the migraine therapeutics market growth during the next few years.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our report on migraine therapeutics market covers the following areas:

  • Migraine therapeutics market sizing
  • Migraine therapeutics market forecast
  • Migraine therapeutics market industry analysis

Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading migraine therapeutics market vendors that include AbbVie Inc., Amgen Inc., Eli Lilly and Co., eNeura Inc., GlaxoSmithKline Plc, Grunenthal GmbH, H. Lundbeck AS, Pfizer Inc., Teva Pharmaceutical Industries Ltd., and Upsher-Smith Laboratories LLC. Also, the migraine therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast an accurate market growth.

Table of Contents

Executive Summary

  • Market Overview

Market Landscape

  • Market ecosystem
  • Market characteristics
  • Value chain analysis

Market Sizing

  • Market definition
  • Market segment analysis
  • Market size 2020
  • Market outlook: Forecast for 2020 - 2025

Five Forces Analysis

  • Five forces summary
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

Market Segmentation by Product

  • Market segments
  • Comparison by Product
  • Drugs - Market size and forecast 2020-2025
  • Devices - Market size and forecast 2020-2025
  • Market opportunity by Product

Market Segmentation by Treatment

  • Preventive treatment
  • Abortive treatment

Customer landscape

Geographic Landscape

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2020-2025
  • Europe - Market size and forecast 2020-2025
  • Asia - Market size and forecast 2020-2025
  • ROW - Market size and forecast 2020-2025
  • Key leading countries
  • Market opportunity by geography
  • Market drivers
  • Market challenges
  • Market trends

Vendor Landscape

  • Vendor landscape
  • Landscape disruption
  • Competitive scenario

Vendor Analysis

  • Vendors covered
  • Market positioning of vendors
  • AbbVie Inc.
  • Amgen Inc.
  • Eli Lilly and Co.
  • eNeura Inc.
  • GlaxoSmithKline Plc
  • Grunenthal GmbH
  • H. Lundbeck AS
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Upsher-Smith Laboratories LLC

Appendix

  • Scope of the report
  • Currency conversion rates for US$
  • Research methodology
  • List of abbreviations

Exhibit

  • 1: Key Finding 1
  • 2: Key Finding 2
  • 3: Key Finding 3
  • 4: Key Finding 5
  • 5: Key Finding 6
  • 6: Key Finding 7
  • 7: Key Finding 8
  • 8: Parent market
  • 9: Market characteristics
  • 10: Offerings of vendors included in the market definition
  • 11: Market segments
  • 12: Global - Market size and forecast 2020 - 2025 ($ million)
  • 13: Global market: Year-over-year growth 2020 - 2025 (%)
  • 14: Five forces analysis 2020 & 2025
  • 15: Bargaining power of buyers
  • 16: Bargaining power of suppliers
  • 17: Threat of new entrants
  • 18: Threat of substitutes
  • 19: Threat of rivalry
  • 20: Market condition - Five forces 2020
  • 21: Product - Market share 2020-2025 (%)
  • 22: Comparison by Product
  • 23: Drugs - Market size and forecast 2020-2025 ($ million)
  • 24: Drugs - Year-over-year growth 2020-2025 (%)
  • 25: Devices - Market size and forecast 2020-2025 ($ million)
  • 26: Devices - Year-over-year growth 2020-2025 (%)
  • 27: Market opportunity by Product
  • 28: Customer landscape
  • 29: Market share by geography 2020-2025 (%)
  • 30: Geographic comparison
  • 31: North America - Market size and forecast 2020-2025 ($ million)
  • 32: North America - Year-over-year growth 2020-2025 (%)
  • 33: Europe - Market size and forecast 2020-2025 ($ million)
  • 34: Europe - Year-over-year growth 2020-2025 (%)
  • 35: Asia - Market size and forecast 2020-2025 ($ million)
  • 36: Asia - Year-over-year growth 2020-2025 (%)
  • 37: ROW - Market size and forecast 2020-2025 ($ million)
  • 38: ROW - Year-over-year growth 2020-2025 (%)
  • 39: Key leading countries
  • 40: Market opportunity by geography ($ million)
  • 41: Impact of drivers and challenges
  • 42: Vendor landscape
  • 43: Landscape disruption
  • 44: Industry risks
  • 45: Vendors covered
  • 46: Market positioning of vendors
  • 47: AbbVie Inc. - Overview
  • 48: AbbVie Inc. - Business segments
  • 49: AbbVie Inc. - Key offerings
  • 50: AbbVie Inc. - Key customers
  • 51: AbbVie Inc. - Segment focus
  • 52: Amgen Inc. - Overview
  • 53: Amgen Inc. - Business segments
  • 54: Amgen Inc. - Key offerings
  • 55: Amgen Inc. - Key customers
  • 56: Amgen Inc. - Segment focus
  • 57: Eli Lilly and Co. - Overview
  • 58: Eli Lilly and Co. - Business segments
  • 59: Eli Lilly and Co. - Key offerings
  • 60: Eli Lilly and Co. - Key customers
  • 61: Eli Lilly and Co. - Segment focus
  • 62: eNeura Inc. - Overview
  • 63: eNeura Inc. - Product and service
  • 64: eNeura Inc. - Key offerings
  • 65: eNeura Inc. - Key customers
  • 66: eNeura Inc. - Segment focus
  • 67: GlaxoSmithKline Plc - Overview
  • 68: GlaxoSmithKline Plc - Business segments
  • 69: GlaxoSmithKline Plc - Key offerings
  • 70: GlaxoSmithKline Plc - Key customers
  • 71: GlaxoSmithKline Plc - Segment focus
  • 72: Grunenthal GmbH - Overview
  • 73: Grunenthal GmbH - Product and service
  • 74: Grunenthal GmbH - Key offerings
  • 75: Grunenthal GmbH - Key customers
  • 76: Grunenthal GmbH - Segment focus
  • 77: H. Lundbeck AS - Overview
  • 78: H. Lundbeck AS - Business segments
  • 79: H. Lundbeck AS - Key offerings
  • 80: H. Lundbeck AS - Key customers
  • 81: H. Lundbeck AS - Segment focus
  • 82: Pfizer Inc. - Overview
  • 83: Pfizer Inc. - Business segments
  • 84: Pfizer Inc. - Key offerings
  • 85: Pfizer Inc. - Key customers
  • 86: Pfizer Inc. - Segment focus
  • 87: Teva Pharmaceutical Industries Ltd. - Overview
  • 88: Teva Pharmaceutical Industries Ltd. - Business segments
  • 89: Teva Pharmaceutical Industries Ltd. - Key offerings
  • 90: Teva Pharmaceutical Industries Ltd. - Key customers
  • 91: Teva Pharmaceutical Industries Ltd. - Segment focus
  • 92: Upsher-Smith Laboratories LLC - Overview
  • 93: Upsher-Smith Laboratories LLC - Product and service
  • 94: Upsher-Smith Laboratories LLC - Key offerings
  • 95: Upsher-Smith Laboratories LLC - Key customers
  • 96: Upsher-Smith Laboratories LLC - Segment focus
  • 97: Currency conversion rates for US$
  • 98: Research Methodology
  • 99: Validation techniques employed for market sizing
  • 100: Information sources
  • 101: List of abbreviations